By Dr. Lei Deng Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology University of Washington/Fred Hutchinson Cancer Center https://youtu.be/QVW-vify1x8 Transcript: Dr.
Author: Dr. Arya Mariam Roy from Roswell Park Comprehensive Cancer Center What are antibody drug conjugates (ADCs)? Antibody drug conjugates (ADCs) are newer
MARIPOSA-2: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor
By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated
Bellevue, WA – October 24, 2024 The Binaytara Foundation, a leading global cancer non-profit organization dedicated to improving access to cancer care,
ESMO 2023 Update – KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author: Lei Deng,
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung Cancer
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant
LIBRETTO-431: Randomized phase III study of selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive advanced NSCLC Author: Dr. Anam Kamal Selpercatinib is a
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III Non-Small Cell